-
公开(公告)号：US10688180B2
公开(公告)日：2020-06-23
申请号：US15703126
申请日：2017-09-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Innate Pharma
Inventor： Robert F. Graziano , Ashok K. Gupta , Su Young Kim , Jon Wigginton , Pascale Andre
Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.
-
公开(公告)号：US09789182B2
公开(公告)日：2017-10-17
申请号：US14437029
申请日：2013-10-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Innate Pharma
Inventor： Robert F. Graziano , Ashok K. Gupta , Su Young Kim , Jon Wigginton , Pascale Andre
IPC: A61K39/395 , C07K16/28 , A61K39/00
CPC classification number: A61K39/3955 , A61K2039/507 , A61K2039/545 , C07K16/2803 , C07K16/2818 , C07K2317/565 , C07K2317/92
Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.
-
公开(公告)号：US20150283234A1
公开(公告)日：2015-10-08
申请号：US14437029
申请日：2013-10-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY , INNATE PHARMA
Inventor： Robert F. Graziano , Ashok K. Gupta , Su Young Kim , Jon Wigginton , Pascale Andre
IPC: A61K39/395 , C07K16/28
CPC classification number: A61K39/3955 , A61K2039/507 , A61K2039/545 , C07K16/2803 , C07K16/2818 , C07K2317/565 , C07K2317/92
Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.
Abstract translation: 提供了使用抗-KIR抗体与抗CTLA-4抗体组合的临床治疗癌症（例如实体瘤或血液恶性肿瘤）的方法。
-
公开(公告)号：US12037392B2
公开(公告)日：2024-07-16
申请号：US17225160
申请日：2021-04-08
Applicant: INNATE PHARMA
Inventor： Pascale Andre , Mathieu Blery , Carine Paturel , Caroline Soulas , Nicolaï Wagtmann
IPC: C07K16/30 , A61K39/395 , C07K16/28 , A61K39/00
CPC classification number: C07K16/2803 , A61K39/39558 , C07K16/2863 , C07K16/30 , A61K2039/505 , A61K2039/545 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/76 , C07K2317/92 , A61K39/39558 , A61K2300/00
Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
-
公开(公告)号：US11225519B2
公开(公告)日：2022-01-18
申请号：US16448016
申请日：2019-06-21
Applicant: INNATE PHARMA
Inventor： Pascale Andre , Mathieu Blery , Caroline Soulas , Nicolai Wagtmann
Abstract: The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.
-
Patent Agency Ranking
公开(公告)号：US10711063B2
公开(公告)日：2020-07-14
申请号：US15511778
申请日：2015-09-15
Applicant: INNATE PHARMA
Inventor： Pascale Andre , Mathieu Blery , Carine Paturel , Nicolai Wagtmann
IPC: A61K39/395 , C07K16/28 , C07K16/30 , A61K39/00
Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
-
公开(公告)号：US11572410B2
公开(公告)日：2023-02-07
申请号：US16924288
申请日：2020-07-09
Applicant: INNATE PHARMA
Inventor： Pascale Andre , Mathieu Blery , Carine Paturel , Nicolai Wagtmann
IPC: A61K39/395 , C07K16/28 , C07K16/30 , A61K39/00
Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
-
公开(公告)号：US10160810B2
公开(公告)日：2018-12-25
申请号：US14594353
申请日：2015-01-12
Applicant: INNATE PHARMA, S.A. , UNIVERSITY OF GENOVA
Inventor： Alessandro Moretta , Emanuela Marcenaro , Francois Romagne , Pascale Andre
IPC: A61K39/395 , C07K16/28 , A61K45/06 , G01N33/569 , A61K39/00
Abstract: The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders.
-
公开(公告)号：US20150344576A1
公开(公告)日：2015-12-03
申请号：US14829170
申请日：2015-08-18
Applicant: Novo Nordisk A/S - Novo Alle , Innate Pharma S.A.S. , University of Genoa
Inventor： Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurent Gauthier , Francois Romagne , Peter Andreas Nicolai Reumert Wagtmann , Ivan Svendsen , Stefan Zahn , Anders Svensson , Matthias Thorolfsson , Soren Berg Padkaer , Kristian Kjaergaard , Pieter Johannes Louis Spee , Michael Wilken
IPC: C07K16/28
CPC classification number: C07K16/42 , C07K16/28 , C07K16/2803 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.
Abstract translation: 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许哺乳动物受试者中NK细胞细胞毒性增强的抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。
-
公开(公告)号：US20150191547A1
公开(公告)日：2015-07-09
申请号：US14659045
申请日：2015-03-16
Applicant: Novo Nordisk A/S - Novo Alle , Innate Pharma S.A.S. , University of Genoa
Inventor： Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurent Gauthier , Francois Romagne , Peter Andreas Nicolai Reumert Wagtmann , Ivan Svendsen , Stefan Zahn , Anders Svensson , Matthias Thorolfsson , Soren Berg Padkaer , Kristian Kjaergaard , Pieter Johannes Louis Spee , Michael Wilken
IPC: C07K16/42
CPC classification number: C07K16/42 , C07K16/28 , C07K16/2803 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.039 seconds)
